ANGPTL3 Deficiency and Risk of Hepatic Steatosis

Abstract

ANGPTL3 deficiency related to LoF mutations in <i>ANGPTL3</i>, as well as genetically determined reduction of plasma ANGPTL3 levels, is not associated with hepatic steatosis. Therapeutic approaches to inhibit ANGPTL3 production in hepatocytes are not necessarily expected to result in the increased risk for hepatic steatosis that was observed with vupanorsen.